TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31997236

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment with Huoxue Xiaoyi Granule before ovulation and Bushen Zhuyun Granule after ovulation for 6 menstrual cycles.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo control group receiving placebo treatment for 6 menstrual cycles.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Adverse events comparison between groups.
Number of subjects: 202
Study: 30940414

Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily for 6 days
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily for 10 days
Number of subjects: 1333
Study: 27837268

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (7000 IU/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 25231512

Group type: EXPERIMENTAL
Intervention: ACT-280778 10 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: All groups (placebo, ACT-280778, amlodipine)
Number of subjects: 155
Study: 24168077

Group type: EXPERIMENTAL
Intervention: NASHA hyaluronic acid
Number of subjects: 218

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: NASHA hyaluronic acid (post-hoc subgroup analysis)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Saline control (post-hoc subgroup analysis)
Number of subjects: 218
Study: 22955399

Group type: EXPERIMENTAL
Intervention: Shoulder hemiarthroplasty
Number of subjects: 32

Group type: COMPARATOR
Intervention: ORIF with locking plate
Number of subjects: 32
Study: 19546359

Group type: EXPERIMENTAL
Intervention: Weekly L-AMB dosing (7.5 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single L-AMB dose (15 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Daily L-AMB dosing (1 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall infusion-related reactions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nephrotoxicity
Number of subjects: 24
Study: 18322594

Group type: EXPERIMENTAL
Intervention: 90 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 60 micrograms recombinant hepatitis B vaccine + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo + IFN alpha 1b 50 micrograms 3 times a week for 24 weeks
Number of subjects: 72
Study: 15635558

Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 120
Study: 11903083

Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 122
Study: 10371878

Group type: EXPERIMENTAL
Intervention: CPC mouthrinse (0.05% cetylpyridinium chloride)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control mouthrinse
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: CPC mouthrinse
Number of subjects: 111
Study: 8549061

Group type: EXPERIMENTAL
Intervention: Acute caffeine ingestion (250 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acute caffeine ingestion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chronic caffeine use
Number of subjects: 9
Study: 2244841

Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging of the intracranial optic nerves and chiasm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging of the orbital optic nerves
Number of subjects: 15
Study: 346138

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Truncal vagotomy and antrectomy (TVA)
Number of subjects: 222
Study: 31279078

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ticagrelor (with Omeprazole)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ticagrelor (with Placebo)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (Omeprazole and Placebo)
Number of subjects: 86
Study: 30670313

Group type: EXPERIMENTAL
Intervention: Mitomycin‐C dissolved in an alkaline wash plus rifampicin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rifampicin and alkaline nasal wash
Number of subjects: 50
Study: 28277054

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for erythema migrans (specific regimens not detailed in the abstract)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for erythema migrans
Number of subjects: 188
Study: 25758598

Group type: EXPERIMENTAL
Intervention: Action research process using the social educational process known as PLA
Number of subjects: 0
Study: 23835707

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² on day 1 of 21-day cycles; n = 359)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo (n = 180)
Number of subjects: 539
Study: 21736786

Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration plus a diuretic (DD; 40 mg furosemide)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exercise-induced dehydration plus placebo (DN)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Exercise while maintaining euhydration plus placebo (EU; control condition)
Number of subjects: 26
Study: 19756431

Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response evaluation or prediction after neoadjuvant chemotherapy
Number of subjects: 0
Study: 16777385

Group type: EXPERIMENTAL
Intervention: Treatment responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adherent patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 0
Study: 15305227

Group type: EXPERIMENTAL
Intervention: 1,000 mU/l prolactin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100 ng/ml leptin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prolactin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 5
Study: 10402679

Group type: EXPERIMENTAL
Intervention: Mimicry by confederates of participants' posture and movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispositionally empathic individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor behavior of participants
Number of subjects: 0
Study: 7578537

Group type: EXPERIMENTAL
Intervention: Mail distribution of health education materials
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: General practitioner distribution of health education materials
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Perceived acceptability of materials (both groups)
Number of subjects: 512
Study: 2126147

Group type: EXPERIMENTAL
Intervention: Ranitidine (2 x 150 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Enprostil (2 x 35 micrograms)
Number of subjects: 8
Study: 7466216

Group type: EXPERIMENTAL
Intervention: Uncrossed reaction times
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Crossed reaction times
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulus eccentricity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nasal hemiretina stimulation at 35°
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Global speed of the two hemiretinas
Number of subjects: 20
Study: 29969700

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 302

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 302
Study: 27806213

Group type: EXPERIMENTAL
Intervention: Laser intra‐hemorrhoidal coagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 24769014

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) maintenance therapy, 10 mg daily, given on days 1 to 21 of 28-day cycles for 12 months after alloHCT.
Number of subjects: 30
Study: 22176632

Group type: EXPERIMENTAL
Intervention: High-GI meals consumed predominantly late (supper)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-GI meals consumed predominantly early (breakfast)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High energy consumed in the evening meal pattern
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-GI diet consumed predominantly early in the day
Number of subjects: 6
Study: 19948383

Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oxycodone 20mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Oxycodone 0mg (placebo)
Number of subjects: 29
Study: 17622361

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 20

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 20
Study: 15737169

Group type: EXPERIMENTAL
Intervention: Porridge group (fruit- and fibre-rich porridge)
Number of subjects: 20
Study: 11888836

Group type: EXPERIMENTAL
Intervention: Two daily subcutaneous injections of hexarelin (1.5 microg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Three daily subcutaneous injections of hexarelin (1.5 microg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous hexarelin (1 microg/kg) at the end of each 24-h sampling period
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prior hexarelin administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 6
Study: 10442376

Group type: EXPERIMENTAL
Intervention: UFT 300 mg/m2 plus calcium folinate 90 mg (divided into three doses per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel starting at 50 mg/m2, escalated in 10 mg/m2 steps
Number of subjects: 0
Study: 8522637

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 25 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 35 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 50 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 60 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 75 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 90 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 100 mg three times a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xanomeline tartrate 115 mg three times a day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2189709

Group type: EXPERIMENTAL
Intervention: Prophylactic drainage (drain placed)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No prophylactic drainage (no drain placed)
Number of subjects: 113
Study: 6459255

Group type: EXPERIMENTAL
Intervention: HNN cream (halcinonide, neomycin, and nystatin)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: BGI cream (betamethasone valerate, gentamicin, iodochlorhydroxyquin, and tolnaftate)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: HNN cream
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: BGI cream
Number of subjects: 154
Study: 31378863

Group type: EXPERIMENTAL
Intervention: 10-20-30 training
Number of subjects: 60

Group type: COMPARATOR
Intervention: 30-30 training
Number of subjects: 60
Study: 28160355

Group type: EXPERIMENTAL
Intervention: Bilateral VIM-DBS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unilateral right-hemispheric VIM-DBS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unilateral left-hemispheric VIM-DBS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inactivated VIM-DBS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Syllable duration
Number of subjects: 16
Study: 26331880

Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.325 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.65 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administration (0.00 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.00 g/kg)
Number of subjects: 20
Study: 25608549

Group type: EXPERIMENTAL
Intervention: Military Mental Health Promotion Program (email based cognitive behavioral intervention)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (non-equivalent control group)
Number of subjects: 32
Study: 21853694

Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) Programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19730388

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Escitalopram 30 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Escitalopram (both doses)
Number of subjects: 30
Study: 17540218

Group type: EXPERIMENTAL
Intervention: Emotional Disclosure (ED) intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard control writing intervention
Number of subjects: 59
Study: 16763926

Group type: EXPERIMENTAL
Intervention: TAPP (Transabdominal Preperitoneal)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: TEP (Totally Extraperitoneal)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open Lichtenstein hernioplasty
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: TAPP and TEP
Number of subjects: 82
Study: 15190235

Group type: EXPERIMENTAL
Intervention: Gabapentin (up to a maximum dose of 2,400 mg/d in three doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10913030

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (DWL, n = 14)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (EWL, n = 14)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (C, n = 8)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise with weight maintenance (EWS, n = 16)
Number of subjects: 52
Study: 8843294

Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study: 1839998

Group type: EXPERIMENTAL
Intervention: New oral preparation of medroxyprogesterone acetate (200‐mg sachet, twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard formulation (Farlutal, 500‐mg tablet, twice daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: New oral preparation of medroxyprogesterone acetate
Number of subjects: 22
Study: 6133977

Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study: 30508132

Group type: EXPERIMENTAL
Intervention: Higher perceived organizational resources
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Better staff motivation
Number of subjects: 253
Study: 28799443

Group type: EXPERIMENTAL
Intervention: Personalized education on environmental fall prevention recommendations
Number of subjects: 24

Group type: COMPARATOR
Intervention: Generalized education on environmental fall prevention recommendations
Number of subjects: 24
Study: 26976734

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: High FODMAP diet
Number of subjects: 40
Study: 26316042

Group type: EXPERIMENTAL
Intervention: High-protein/low-carbohydrate diet (diet HP)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet S)
Number of subjects: 193
Study: 24573334

Group type: EXPERIMENTAL
Intervention: Adherence to Scottish Intercollegiate Guidelines Network guideline for the diagnosis and assessment of ASD after medical training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Initial specialist appointment diagnosis of ASD
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Use of recommended discretionary structured observational instrument
Number of subjects: 90
Study: 22906140

Group type: EXPERIMENTAL
Intervention: 3.5-ms waveform
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 4.5-ms waveform
Number of subjects: 121
Study: 19387901

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB) - losartan (25‐50 mg, n = 5), candesartan (4‐8 mg, n = 4), valsartan (80 mg, n = 1), telmisartan (40 mg, n = 2), olmesartan (10 mg, n = 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 13
Study: 17460018

Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 100

Group type: COMPARATOR
Intervention: RV apical pacing
Number of subjects: 100
Study: 15293073

Group type: EXPERIMENTAL
Intervention: Conventional influenza split vaccine (SpV)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted subunit vaccine (aSuV)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Virosome‐based subunit vaccine (vSuV)
Number of subjects: 840

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 840
Study: 11450720

Group type: EXPERIMENTAL
Intervention: Disposable tonometer prism
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Goldmann tonometer prism
Number of subjects: 100
Study: 9491898

Group type: EXPERIMENTAL
Intervention: Stable patients during hemodialysis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unstable patients during hemodialysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stable patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unstable patients
Number of subjects: 30
Study: 8113059

Group type: EXPERIMENTAL
Intervention: CATCH intervention targeting cardiovascular health behaviors (dietary intake of fat and sodium, physical activity, tobacco use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schools (not specified)
Number of subjects: 0
Study: 3245857

Group type: EXPERIMENTAL
Intervention: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bezafibrate sustained release tablet (Cedur retard, 400 mg) taken in the evening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30198163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 27993435

Group type: EXPERIMENTAL
Intervention: Modified patient education program
Number of subjects: 424

Group type: COMPARATOR
Intervention: Usual lecture-based education program
Number of subjects: 424
Study: 26093863

Group type: EXPERIMENTAL
Intervention: High-dose statin recapture therapy given orally 12 and 2 hours before CABG
Number of subjects: 2630

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: High-dose statin recapture therapy
Number of subjects: 2630
Study: 23732189

Group type: EXPERIMENTAL
Intervention: Combination therapy (60 mg/day duloxetine + 300 mg/day pregabalin)
Number of subjects: 804

Group type: COMPARATOR
Intervention: High-dose monotherapy (120 mg/day duloxetine or 600 mg/day pregabalin)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 804

Group type: COMPARATOR
Intervention: High-dose monotherapy
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: 60 mg/day duloxetine
Number of subjects: 804
Study: 22137511

Group type: EXPERIMENTAL
Intervention: IV tranexamic acid 10 mg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sterile water 0.1 mL/kg (placebo group)
Number of subjects: 84
Study: 19329697

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 100
Study: 16997399

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard echocardiography
Number of subjects: 0
Study: 15105234

Group type: EXPERIMENTAL
Intervention: 45 degrees-rotation group, n = 24
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group, n = 24
Number of subjects: 48
Study: 12133743

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 94
Study: 10426682

Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7497205

Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Male
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Female
Number of subjects: 646
Study: 2321721

Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25% (1 ml/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Rectal diclofenac 0.25 mg/kg
Number of subjects: 43
Study: 6985789

Group type: EXPERIMENTAL
Intervention: Standard therapy plus selective intra‐arterial vasopressin infusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 38
Study: 30744647

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program intervention 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program intervention 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28645058

Group type: EXPERIMENTAL
Intervention: Free physical activity classes over a 6-month period
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Frequent user program with prizes for park visits
Number of subjects: 1445

Group type: EXPERIMENTAL
Intervention: Both free physical activity classes and frequent user program
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Neither intervention (control condition)
Number of subjects: 1445
Study: 26491815

Group type: EXPERIMENTAL
Intervention: Community health worker intervention during the trial (DCAS)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Community health worker intervention during the first year after DCAS (control group intervention)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care during DCAS (control group)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Community health worker intervention during the control group's intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: Year after the control group's intervention
Number of subjects: 268